1. United States of America Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
Invizyne Technologies Inc. Common Stock

Invizyne Technologies Inc. Common Stock

IZTC
Invizyne Technologies Inc. Common StockUS flagNASDAQ Global Market
16.50
USD
+1.00
- -
157.23MMarket Cap
Invizyne Technologies Inc. Common Stock
IZTC
(NASDAQ Global Market)

Recent

price

16.50

P/E

ratio

- -

div

yld

- -

ROIC.AI

2021
2022
2023
2024
TTM
FRC
- -
- -
- -
- -
- -
Revenue per Share
-0.15
-0.17
-0.25
- -
-0.72
Basic EPS, GAAP
-0.25
-0.18
-0.18
- -
-1.1
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
Dividend per Share
-0.33
-0.5
-0.75
- -
-1.47
Book Value per Share
0.15
0.17
-0.05
- -
1.28
Tangible Book Value per Share
8
8
8
- -
8
Basic Weighted Avg Shares
- -
- -
- -
- -
- -
Sales/Revenue/Turnover
- -
- -
- -
- -
- -
Operating Margin (%)
- -
- -
- -
- -
- -
Depreciation Expense
-1
-1
-2
-6
-6
Net Income, GAAP
- -
- -
- -
- -
- -
Effective Tax Rate (%)
- -
- -
- -
- -
- -
Profit Margin (%)
1
1
-1
9
9
Working Capital
1
- -
1
1
1
LT Debt
1
1
- -
10
10
Total Equity
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Jun'24
Sep'24
Dec'24
ST Debt
3
4
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
1
1
1
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
8
8
8
Market Capitalization
- -
- -
134

Working Capital

FRC

•

in mil. unless spec.
Jun'24
Sep'24
Dec'24
Total Current Assets
2
1
11
Cash, Cash Equivalents & STI
- -
- -
10
Accounts Receivable, Net
- -
- -
- -
Inventories
- -
- -
- -
Total Current Liabilities
5
6
1
Payables & Accruals
1
1
1
ST Debt
3
4
- -
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
- -
-2,811.49%
Free Cash Flow
- -
- -
505.76%
Net Income, GAAP
- -
- -
187.55%
Sales/Revenue/Turnover
- -
- -
- -
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2022
- -
- -
- -
- -
- -
2023
- -
- -
- -
- -
- -
2024
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2022
- -
- -
- -
- -
-0.17
2023
-0.03
- -
-0.06
- -
-0.25
2024
-0.12
- -
-0.2
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2022
- -
- -
- -
- -
- -
2023
- -
- -
- -
- -
- -
2024
- -
- -
- -
- -
- -
Similar Companies
NervGen Pharma Corp. Common stock (NGEN)
CSL Limited (CSL.AX)
Medy-Tox Inc. (086900.KQ)
Gemina Laboratories Ltd. (GLABF)
Anti-Microbial Savior BioteQ Co., Ltd (6864.TWO)
Dyne Therapeutics, Inc. (DYN)
Business
Invizyne Technologies, Inc., soon to be known as eXoZymes, Inc. with a ticker change to EXOZ expected February 12, 2025, is a biomanufacturing firm operating in the United States. The company innovates through its SimplePath platform, which harnesses cell-free, enzyme-driven systems to create an array of commercially significant molecules from renewable resources. This proprietary technology is designed to produce diverse chemicals such as active pharmaceutical ingredients, advanced biofuels like sustainable aviation fuel, food ingredients, and specialty compounds. The SimplePath approach seeks to offer an efficient and sustainable alternative to conventional chemical synthesis and cell-based methods. Founded in 2019, the company is headquartered in Monrovia, California.

Company News

APIChat

  • defenseworld.net

    Invizyne Technologies (NASDAQ:IZTC) Shares Down 1.2% – Time to Sell?

  • defenseworld.net

    Invizyne Technologies (NASDAQ:IZTC) Trading 2.2% Higher – Here’s Why

  • defenseworld.net

    Protalix BioTherapeutics (NYSE:PLX) vs. Invizyne Technologies (NASDAQ:IZTC) Critical Survey